Hence, nanocarriers to deliver TRAP-1 inhibitors were developed in which iron oxide nanoparticles (IONs) were conjugated to the Hsp90 inhibitor geldanamycin (GA) and the mitochondria localization signal (MLS) peptide to enable selective tumor targeting (Amash et al., 2020). The gene discussed is TRAP1; the disease is neoplasm.